The National Health Insurance (NHI) is to include more medicines for cancer, osteoporosis, chronic kidney diseases and other diseases, the National Health Insurance Administration (NHIA) said yesterday, adding that the initiative would take effect on Feb. 1 next year at the earliest.
As the number of people with high blood pressure, diabetes and obesity in the nation rises and the onset age of kidney diseases decreases, increasingly more people are on dialysis.
About 100,000 Taiwanese are on kidney dialysis — the highest rate of kidney dialysis patients per capita in the world — and the treatment could cost the NHI system up to NT$50 billion (US$1.53 billion) per year, the agency said, citing data from the Health Promotion Administration.
Photo: Chiu Chih-jou, Taipei Times
NHIA Director-General Shih Chung-liang (石崇良) yesterday said that NT$5.95 billion would be allocated to the NHI fund for reimbursement of drugs for cancer, osteoporosis, chronic renal diseases and other diseases, and it is expected to benefit more than 310,000 people.
A medicine to be included in the NHI benefit catalogue is sodium–glucose cotransporter-2 inhibitors, which could delay deterioration of kidney diseases and reduce the risk of heart failure in clinical trials, he said.
It would be reimbursable for patients with a glomerular filtration rate of 25 to 60, expected to prevent their conditions from worsening to the extent that dialysis is inevitable, Shih said.
However, people would not be eligible for reimbursement without signing up for an early-stage chronic kidney disease integrated care program or a care and health counseling project for patients with renal disease, he said.
The agency would require people to change their lifestyle and track their renal function to qualify, he said.
The reimbursement is projected to benefit 153,000 patients with renal diseases, while the listing of medicine for chronic systolic heart failure would benefit 16,000 people, Shih said, adding that the annual total expenditure would be up to NT$1.6 billion.
In terms of cancer drugs, immune checkpoint inhibitors, or immuno-oncology (IO) therapies, were added to the catalogue, including durvalumab and tremelimumab, which are applicable to patients with liver or bile duct cancer, Shih said, adding that it would benefit 1,938 people with an annual expense of about NT$1.28 billion.
The combination of durvalumab and tremelimumab is a dual IO therapy applicable to liver cancer based on international standards, he said.
For the first time, IO therapies are to be approved for bile duct cancer, which is highly malignant and has few therapy options. They are to be used in small cell lung cancer as well, he added.
Trastuzumab deruxtecan would also be reimbursable for patients with human epidermal growth factor receptor 2-positive breast cancer, which is expected to benefit 1,172 people by saving NT$1.46 million of medicine expenditure per capita a year, Shih said.
The annual NHI reimbursement for the therapy would total NT$1.59 billion, he said.
Bevacizumab, a targeted therapy drug for colorectal cancer, would be listed as a second-line therapy and benefit 842 people, with an annual NHI reimbursement of about NT$202 million, he said.
As Taiwan ages, medicines for osteoporosis would be part of primary prevention for people with high-risk factors, he said, adding that secondary prevention would be expanded to cover people with radius or humerus fractures.
GEARING UP: An invasion would be difficult and would strain China’s forces, but it has conducted large-scale training supporting an invasion scenario, the report said China increased its military pressure on Taiwan last year and took other steps in preparation for a potential invasion, an annual report published by the US Department of Defense on Wednesday showed. “Throughout 2023, Beijing continued to erode longstanding norms in and around Taiwan by employing a range of pressure tactics against Taiwan,” the report said, which is titled “Military and Security Developments Involving the People’s Republic of China (PRC) 2024.” The Chinese People’s Liberation Army (PLA) “is preparing for a contingency to unify Taiwan with the PRC by force, if perceived as necessary by Beijing, while simultaneously deterring, delaying or denying
PEACEFUL RESOLUTION: A statement issued following a meeting between Australia and Britain reiterated support for Taiwan and opposition to change in the Taiwan Strait Canada should support the peaceful resolution of Taiwan’s destiny according to the will of Taiwanese, Canadian lawmakers said in a resolution marking the second anniversary of that nation’s Indo-Pacific strategy on Monday. The Canadian House of Commons committee on Canada-Chinese relations made the comment as part of 34 recommendations for the new edition of the strategy, adding that Ottawa should back Taiwan’s meaningful participation in international organizations. Canada’s Indo-Pacific Strategy, first published in October 2022, emphasized that the region’s security, trade, human rights, democracy and environmental protection would play a crucial role in shaping Canada’s future. The strategy called for Canada to deepen
TECH CONFERENCE: Input from industry and academic experts can contribute to future policymaking across government agencies, President William Lai said Multifunctional service robots could be the next new area in which Taiwan could play a significant role, given its strengths in chip manufacturing and software design, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) chairman and chief executive C.C. Wei (魏哲家) said yesterday. “In the past two months, our customers shared a lot of their future plans with me. Artificial intelligence [AI] and AI applications were the most talked about subjects in our conversation,” Wei said in a speech at the National Science and Technology Conference in Taipei. TSMC, the world’s biggest contract chipmaker, counts Nvidia Corp, Advanced Micro Devices Inc, Apple Inc and
LEAP FORWARD: The new tanks are ‘decades more advanced than’ the army’s current fleet and would enable it to compete with China’s tanks, a source said A shipment of 38 US-made M1A2T Abrams tanks — part of a military procurement package from the US — arrived at the Port of Taipei early yesterday. The vehicles are the first batch of 108 tanks and other items that then-US president Donald Trump announced for Taiwan in 2019. The Ministry of National Defense at the time allocated NT$40.5 billion (US$1.25 billion) for the purchase. To accommodate the arrival of the tanks, the port suspended the use of all terminals and storage area machinery from 6pm last night until 7am this morning. The tanks are expected to be deployed at the army’s training
RSS